Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02427204 · ClinicalTrials.gov registry record
Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality
A clinical trial of Hepatitis C Infection, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT02427204: Completed study of Hepatitis C Infection, sponsored by Icahn School of Medicine at Mount Sinai.
NCT02427204 is a study of Hepatitis C Infection that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 150 participants, below the 1,333-participant average among 3 other Hepatitis C Infection trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02427204, a study of Hepatitis C Infection, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The main questions being addressed are (1) how patient reported outcomes change during treatment for HCV, (2) how treatment impacts liver function and liver status, and (3) how much treatment costs from the payer's perspective and the patient's perspective. The hypothesis being tested is that treatment has a negative effect on the quality of life during treatment. The negative effect is expected to be temporary. Successful treatment, which is equated with a virological cure of the infection, is expected to result in an improvement in quality of life compared to baseline and to improvement in markers of liver function and liver status. Costs of treatment are expected to be $80,000-$200,000 per virological cure.
Primary Outcome
Change in vitality score at week 24 as compared to baseline
Conditions Studied
Study Locations (1)
New York
- Icahn School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-01-18 |
What the finished NCT02427204 record still lists
NCT02427204 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,333-participant average among 3 other Hepatitis C Infection trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Hepatitis C Infection appearing as the primary indexed condition, and to 0 interventions.
NCT02427204 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02427204 about?
NCT02427204 is a clinical study titled "Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality". The main questions being addressed are (1) how patient reported outcomes change during treatment for HCV, (2) how treatment impacts liver function and liver status, and (3) how much treatment costs from the payer's perspective and the patient's perspective. The hypothesis being tested is that treatm...
What is the current status of trial NCT02427204?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2015-06. Estimated completion is 2018-01-18.
What conditions does trial NCT02427204 study?
This clinical trial studies the following conditions: Hepatitis C Infection.
Who is sponsoring clinical trial NCT02427204?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02427204 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia